In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 mifion units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1*5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine aminotransferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients. (Gut 1993; supplement: S 128-S129) 
Abstract
In a study of 87 patients with chronic hepatitis C, 12 months' treatment with interferon alfa-2b at a dose of 6 mifion units (MU) three times per week seemed to be more effective than treatment with 3 MU three times a week for two months plus 1*5 MU three times a week for 10 months in increasing the percentage of long term responders. The percentage of patients in whom alanine aminotransferase activities returned to normal was highest in the 6 MU group, as was the percentage of responders who sustained this normal activity after treatment. Side effects were moderate and self-limited in most patients. (Gut 1993; supplement: S 128-S129) The efficacy of three different treatment schedules of recombinant interferon (IFN) alfa-2b (INTRON A, Schering-Plough) was evaluated in patients with chronic hepatitis C virus (HCV) infection. Chronic active hepatitis Patients and methods For inclusion in the trial, patients had to be aged between 18 and 65 years, with a white blood cell (WBC) count >3XlO0/l, platelets >1 X 1O"/1, and serum alanine aminotransferase (ALT) activities twice the upper limit of normal for nine months. They were also required to have a histologically proved diagnosis of chronic persistent hepatitis, chronic active hepatitis, chronic lobular hepatitis or compensated cirrhosis, and to be positive for antibodies to hepatitis C virus (anti-HCV) on second generation ELISA (ELISA II, Ortho).
Patients were excluded if they had a history of drug or alcohol abuse; cardiac, renal, or respiratory failure; or positivity for antibodies to HIV or autoimmune antibodies (antinuclear, antimitochondrial, or anti-liver-kidney microsomal-1).
All patients received recombinant interferon alfa-2b for 12 months, according to the following schedule:
Group A: 6 million units (MU) intramuscularly three times weekly for 12 months.
Group B: 3 MU three times weekly subcutaneously for 12 months.
Group C: 3 MU three times weekly subcutaneously for two months followed by 1-5 MU TIW for 10 months.
Clinical and laboratory parameters were evaluated every 15 days for the first two months, and then at monthly intervals. A return of alanine aminotransferase (ALT) activities to normal during IFN treatment was considered a complete response.
Patient characteristics before beginning treatment are shown in the (Fig 1) times weekly for 10 months in increasing the ALT activities remained normal six months percentage of long term responders. This after treatment stopped was 81% in group A, regimen was well tolerated with no appreciable 64-3% in group B, and 43T8% in group C. toxicity. 
